Reig Jofre starts marketing of three new injectble products for hospitals
![](/46/pdcnewsitem/04/54/80/reig%20jofre.png)
Developments correspond to generic products based on specialized pharmaceutical technologies.
Reig Jofre has started the commercialization of three new injectable products for hospitals, developed by the R&D team of the injectable and antibiotic plants that the company has in Barcelona and Toledo, respectively. These developments correspond to generic products based on specialized pharmaceutical technologies.
Bivalirrudine 250 mg (active ingredient, Bivalirrudin) is a lyophilized injectable anticoagulant, indicated in both adult patients who undergo a percutaneous coronary intervention, including patients with myocardial infarction, and in the treatment of adult patients with unstable angina who will be subjected to an urgent or early surgery.
Bivalirrudine has been co-developed by the R&D team of the Barcelona injectable plant in collaboration with AMBIOPHARM, the North American developer and manufacturer of the active ingredient. The product is being registered in 16 markets (US among them) and is already being marketed in Spain, Denmark, Sweden, the UK and Australia. In the coming months, it is expected to start marketing this injectable in other countries.
Palonosetron 5 mg (active ingredient, Palonosetron HCl) is an injectable antiemetic indicated for the prevention of acute nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month old.
Also, developed in the Barcelona injectable plant, Palonestron has been registered in six markets and is already being marketed in Spain, UK, Denmark and Sweden.
Cefepime 1 g (active ingredient, Cefepime-Arginine) is an injectable antibiotic belonging to cephalosporin group, indicated in the treatment of respiratory, urinary and gastric infections, among others, caused by bacteria. This injectable, developed by the R&D team of the Toledo penicillin plant, has been registered in Spain, where it is already marketed.
To market its developments, Reig Jofre has its own sales network in six European markets, and business relationships with 130 partners in 63 countries on five continents. The company confirms its firm commitment to internationalization, whose spearhead is the line of antibiotics and injectable products for hospitals, the latter strongly boosted in 2016 by the entry in Japan.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance